Helena A. Yu, MD

Patient Selection and Sequencing of NSCLC ADCs

August 19th 2024

The panel examines which patient populations might benefit most from treatment with datopotamab deruxtecan (Dato-DXd), sacituzumab govitecan, and patritumab deruxtecan (HER3-DXd). Additionally, they explore potential sequencing strategies for these antibody-drug conjugates in second-line and later treatment settings.

Mitigating Toxicities of Dato-DXd, Sacituzumab Govitecan, and HER3-DXd

August 12th 2024

Benjamin Levy, MD, compares the common toxicities associated with datopotamab deruxtecan (Dato-DXd), sacituzumab govitecan, and patritumab deruxtecan (HER3-DXd), and shares practical tips for managing these toxicities in the clinical setting to optimize patient care and minimize adverse effects.

Key ADC Studies at ASCO 2024

August 12th 2024

Julia Rotow, MD, highlights and discusses other notable antibody-drug conjugate (ADC) data presented at the American Society of Clinical Oncology (ASCO) 2024 annual meeting, providing insights into the potential impact of these findings on the evolving treatment landscape for non-small cell lung cancer (NSCLC).

Challenges and Learnings from EVOKE-01

August 5th 2024

Benjamin Levy, MD, provides an overview of the rationale and study design for the EVOKE-01 trial, which evaluates the efficacy and safety of sacituzumab govitecan in patients with non-small cell lung cancer who have experienced disease progression following treatment with platinum-based chemotherapy and checkpoint inhibitors.

Targeting of HER3: Insights from HERTHENA-Lung01

August 5th 2024

Helena A. Yu, MD, initiates a discussion on the role of HER3 in the development of resistance to EGFR-targeted therapies. She also examines the HERTHENA-Lung01 study and analyzes the emerging data from this trial.

Key Takeaways from TROPION Trials: Implications for NSCLC Treatment Landscape

July 29th 2024

Overview of TROP2 & Potential Role of TROP2-Directed ADCs in NSCLC

July 29th 2024

ASCO 2024 Updates: Novel Approaches in NSCLC Therapy

July 22nd 2024

The panel explores promising novel therapies in the treatment landscape, focusing on new or recently presented data at the American Society of Clinical Oncology (ASCO) 2024 annual meeting, and share their insights on the potential impact of these therapies on future clinical practice.

Optimizing Therapy Selection in EGFR Mutant NSCLC

July 22nd 2024

Helena A. Yu, MD, examines the patient selection criteria for potentially using osimertinib monotherapy, osimertinib plus chemotherapy, or amivantamab combined with lazertinib in the first-line treatment of advanced EGFR-mutant non-small cell lung cancer.

MARIPOSA Study Insights

July 16th 2024

Benjamin Levy, MD, initiates a discussion on the rationale behind using amivantamab and lazertinib as a first-line treatment for EGFR-mutant non-small cell lung cancer and reviews the recently presented efficacy and safety data from the MARIPOSA trial.

Osimertinib Monotherapy vs. Combination Therapy: Patient Selection in EGFR-Mutant Advanced NSCLC

July 16th 2024

The panel discusses which patients with EGFR-mutant non-small cell lung cancer (NSCLC) are more likely to receive frontline treatment with either osimertinib monotherapy or the combination of osimertinib and chemotherapy, based on individual patient characteristics and preferences.

Advancing Treatment for EGFR-Mutant Advanced NSCLC: Lessons from FLAURA2

July 8th 2024

Helena A. Yu, MD, discusses her treatment strategy for patients with EGFR-mutant non-small cell lung cancer (NSCLC), emphasizing current guidelines and standard of care, while Zosia Piotrowska, MD, MHS, examines the key efficacy and safety findings from the FLAURA2 study, which evaluated first-line osimertinib combined with chemotherapy in patients with advanced EGFR-mutant NSCLC.

Navigating Between ADCs in NSCLC

July 8th 2024

The panel examines the characteristics of patients with non-small cell lung cancer (NSCLC) without actionable alterations who might be the best candidates for frontline treatment with either sacituzumab govitecan or datopotamab deruxtecan (Dato-DXd) and identifies the persisting unmet needs for this patient population.

Exploring Dato-DXd Combinations as First-Line Therapy for Advanced NSCLC

July 2nd 2024

Julia Rotow, MD, explores the rationale, study design, and primary endpoints of the AVANZAR trial, which investigated the combination of datopotamab deruxtecan (Dato-DXd), durvalumab, and carboplatin as a first-line treatment for patients with advanced non-small cell lung cancer lacking actionable mutations, and discusses the patient population most likely to benefit from this drug combination.

Exploring the TROPION-Lung04 Study

July 2nd 2024

Benjamin Levy, MD, presents an overview of the TROPION-Lung04 study in the first-line setting, focusing on the toxicity profile and potential impact on clinical practice.

Role of Antibody-Drug Conjugates in NSCLC Treatment: Insights from EVOKE-02

June 24th 2024

Benjamin Levy, MD, leads discussion on the promising potential of antibody-drug conjugates (ADCs) in treating non-small cell lung cancer (NSCLC) with non-actionable mutations, while Helena A. Yu, MD, presents an overview of the EVOKE-02 study, emphasizing key efficacy and safety data that could significantly impact the current treatment landscape.

Treatment Strategies for NSCLC with Non-Actionable Mutations

June 24th 2024

Mark Socinski, MD; Helena A. Yu, MD; Zosia Piotrowska, MD, MHS; Julia Rotow, MD; and Benjamin Levy, MD, provide a concise overview of current first-line treatment options for non-small cell lung cancer (NSCLC), including their approaches for NSCLC with non-actionable mutations and the influence of PD-L1 tumor proportion score status on treatment choices.

Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NSCLC Following EGFR TKI and Platinum-Based Chemotherapy: HERTHENA-Lung01

October 6th 2023

Expert oncologist Helena Yu, MD, reviews data from HERTHENA-Lung01 following the IASLC 2023 World Conference on Lung Cancer and considers how patritumab deruxtecan will fit into clinical practice.

Dr Yu on the Investigation of BL-B01D1 in Lung Cancer

June 22nd 2023

Helena A. Yu, MD, discusses findings from a phase 1 trial investigating the bispecific antibody-drug conjugate BL-B01D1, which is directed against both HER3 and EGFR, in patients with locally advanced or metastatic solid tumors such as non–small cell lung cancer and small cell lung cancer.

Dr. Yu on Treatments for EGFR-Mutant Lung Cancer

April 23rd 2018

Helena A. Yu, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses treatments for EGFR-mutant lung cancer.